共查询到20条相似文献,搜索用时 15 毫秒
1.
Bruno Annibale Gabriele Capurso Gina Martino Cristina Grossi Gianfranco Delle Fave 《International journal of antimicrobial agents》2000,16(4)
Iron deficiency anaemia (IDA) is the most common form of anaemia world-wide. IDA is the simple result of an imbalance between iron loss and absorption. Gastric function with hydrochloric and ascorbic acid is essential for iron absorption. Some strains of Helicobacter pylori are able to acquire iron, competing with the host. A large percentage of patients with atrophic body gastritis (ABG) develop IDA and 61% of them are H. pylori positive. Recent evidence suggests that H. pylori infection could cause IDA in the absence of peptic ulcer or other upper gastrointestinal (GI) tract bleeding lesions. Gastritis extending to the corpus and a high bacterial load are features of these patients. About 70% of IDA patients with ABG or H. pylori gastritis are premenopausal women. Both ABG and H. pylori gastritis should be considered when evaluating the GI tract of patients with iron deficiency anaemia. 相似文献
2.
儿童幽门螺杆菌感染与缺铁性贫血相关性探讨 总被引:1,自引:0,他引:1
目的探讨儿童幽门螺杆菌感染与缺铁性贫血(IDA)的相关性。方法以因慢性腹痛而行胃检查及Hp检测的69例患儿为观察对象,根据检查结果分为Hp阳性慢性胃炎组、Hp阴性慢性胃炎组及Hp阳性胃部镜下无损害组3组,所有病例均检测血红蛋白(Hb)、平均红细胞体积(MCV)、血清铁(SI)、血清铁蛋白(SF)、总铁结合力(TIBC)等IDA指标。比较三组之间的IDA指标和IDA伴发率。结果Hp阴性慢性胃炎组的IDA指标分别与Hp阳性慢性胃炎组、Hp阳性胃部镜下无损害组比较,差异均有统计学意义(P〈0.01,P〈0.05),而Hp阳性慢性胃炎组的IDA指标与Hp阳性胃部镜下无损害组之间比较,则差异无统计学意义(P〉0.05)。Hp阴性慢性胃炎组的IDA伴发率均低于Hp阳性慢性胃炎组和Hp阳性胃部镜下无损害组(P〈0.05),Hp阳性慢性胃炎组与Hp阳性胃部镜下无损害组之间的IDA伴发率比较差异无统计学意义(P〉0.05)。结论儿童幽门螺杆菌感染与缺铁性贫血两者之间的相关性有统计学意义,且较慢性胃炎与缺铁性贫血的关系更为密切。 相似文献
3.
上消化道疾病幽门螺杆菌感染对缺铁性贫血的影响 总被引:5,自引:0,他引:5
江月明 《国际医药卫生导报》2005,11(4):17-19
目的 探讨儿童上消化道疾病幽门螺杆菌(Helicobacter Pylori, HP)感染率及HP感染对儿童缺铁性贫血(Iron Deficiency Anemia, IDA)的影响。方法 2000年6月至2004年6月本院住院及门诊335例患者上消化道疾病患儿,其中缺铁性贫血患儿109例;采用奥林巴斯GIF-V电子胃镜检查,并进行快速尿素酶试验,14C-呼气试验检测;随机选择HP感染阳性和阴性患儿各50例检测血清铁蛋白(SF)、血红蛋白(Hb)、平均红细胞体积(MCV)、红细胞分布宽度(RDW)。结果 胃镜检查检出HP感染61例,检出率占18.2%(61/335)。各年龄组胃十二指肠疾病HP感染率具有显著差异(P<0.05),HP感染与年龄呈显著正相关(r =0.749,P=0.003),随着年龄的增长,上消化道疾病的发生率逐渐升高(P<0.05),消化性溃疡的发生率也随年龄增长而增加(十二指肠溃疡:r=0.726;胃溃疡:r=0.703; P<0.05)。HP感染阳性组与阴性组比较SF、Hb、MCV、RDW差异均有显著性意义(P<0.05);感染HP儿童血清铁蛋白水平明显低于未感染HP儿童。结论 小儿HP感染随年龄增长而增加,HP感染儿童机体铁营养水平降低,是造成或加重儿童机体铁营养不良的独立危险因素,HP感染是IDA的原因之一,在治疗IDA的过程中应注意清除HP感染。 相似文献
4.
5.
6.
目的分析幽门螺杆菌粪便抗原(HpSA)对幽门螺杆菌感染的诊断价值。方法收集304例患者粪便标本,运用ELISA法定性检测HpSA,同时对照用快速尿素酶试验、Gram染色镜检联合检测的胃黏膜标本。结果HpSA的敏感度为96.7%(240/249),特异度为90.1%(44/49),阳性预测值为96.4%(240/249),阴性预测值为80.0%(44/55),准确率为93.4%(284/304)。结论粪便HpSA检测具有操作简便、省时等特点,是较理想的非侵人性的Hp诊断方法。 相似文献
7.
幽门螺杆菌感染与儿童感染胃炎的关系探讨 总被引:2,自引:2,他引:0
目的 进一步探讨幽门螺杆菌(H·pylori)感染在儿童中发病率以及家庭中的传播关系.方法 将我院2000年1月至2005年12月87例儿童胃炎,其中住院20例,门诊67例,做胃镜检查,并做病理学检查,胃黏膜H·pylori的检测.H·pylori阳性44例,H·pylori阴性43例.结果 表明H·pylori感染与儿童胃炎有密切的关系,H·pylori阳性家庭中的感染率为77.3%,H·pylori阴性家庭中的感染率44.2%,有显著差异性(P<0.01).胃镜检查显示慢性浅表性胃炎52.87%,十二指肠球部溃疡19.54%,病理学检查显示慢性浅表性胃炎在H·pylori阳性组轻度占23%,中度50%,在H·pylori阴性组轻度占70%,中度占23%,两组比较有显著差异性(P<0.01).结论 H·pylori感染呈现明显家庭群聚现象.胃黏膜病理变化H·pylori阳性组比H·pylori阴性组严重. 相似文献
8.
目的观察序贯疗法治疗幽门螺杆菌(HP)感染患者的疗效。方法经胃镜检查确诊的慢性胃炎或消化性溃疡且HP阳性患者82例随机分为治疗组和对照组。治疗组(42例)方案为前5d奥美拉唑+阿莫西林,后5d奥美拉唑+克拉霉素+替硝唑;对照组(40例)三联疗法为奥美拉唑+阿莫西林+克拉霉素,疗程7d。结果治疗组Hp根除率92.85%,对照组Hp根除率75.00%,2组比较差异有统计学意义(P<0.05)。结论以奥美拉唑、阿莫西林、克拉霉素、替硝唑组成的10d序贯疗法治疗Hp感染较7d三联疗法有更高的根除率,可提高临床疗效。 相似文献
9.
《Expert opinion on pharmacotherapy》2013,14(3):507-514
Helicobacter pylori, a Gram-negative organism that survives in the deep mucus layer and attaches to the gastric surface cells, is estimated to be present in up to one-half of the US population. Chronic H. pylori infection causes chronic gastritis, peptic ulcer diseases and even gastric cancer. Cure of the infection leads to healing of gastric inflammation, prevention of development of peptic ulcer, as well as accelerated healing of peptic ulcers, and prevention of ulcer recurrence. Treatment of H. pylori has undergone substantial evolution over the past decade. Despite the in vitro susceptibility, results from single or even dual drug therapy is typically unsatisfactory and the best therapy is yet to be defined. The best current therapies for H. pylori infection consist of a proton pump inhibitor (PPI) or ranitidine bismuth citrate and two antibiotics (triple therapies), or bismuth, tetracycline, metronidazole and a PPI (quadruple therapy). Clarithromycin is one of the most useful antimicrobials against H. pylori. It is an acid-stable macrolide with a broad spectrum of antibacterial activity, well absorbed with a wide tissue distribution and with mild side effects. Clarithromycin has a low minimum inhibitory concentration (MIC50) for H. pylori and its effect is potentiated by acid inhibition. When combined with a PPI or ranitidine bismuth citrate and amoxicillin or metronidazole, eradication rates of more than 95% can be achieved with susceptible organisms. However, the prevalence of primary and acquired clarithromycin resistance, which is due to mutations within a conserved loop of 23S rRNA of H. pylori, is increasing. In practice, the presence of clarithromycin resistance usually implies reduced success when clarithromycin-containing regimes are used. There is a need for improved therapies for H. pylori where antibiotic resistance is less of a problem. 相似文献
10.
《Expert opinion on investigational drugs》2013,22(8):1127-1138
Helicobacter pylori infects the stomach of > 50% of the human population worldwide, with higher prevalence in the developing countries. A strict correlation between H. pylori infection and gastroduodenal diseases has been demonstrated, including gastritis, peptic ulcer and gastric cancer. Current therapies against H. pylori consist of an antisecretory plus antibiotics. These therapies are effective in 80 – 90% of the cases; presently, no alternative therapies have been shown to give comparable or better results. There are two main reasons for therapy failure: poor compliance, which results in cure discontinuation, and antibiotic resistance. To overcome the drawbacks inherent to any antibiotic therapy, a prophylactic vaccine seems to be the most reasonable approach. Vaccines have been developed based on data obtained in animal models, a number of which are currently in Phase I clinical trials, in some cases giving encouraging data for safety and immunogenicity. In the absence of any immunological correlate of protection against H. pylori, it will be possible to evaluate the efficacy of these vaccines only in large Phase III clinical trials. 相似文献
11.
M. V. Joshi S. M. Pohujani B. C. Mehta V. N. Acharya N. A. Kshirsasgar 《European journal of clinical pharmacology》1993,45(4):387-388
Summary Iron deficiency is a common nutritional deficiency, which leads to structural functional and enzymatic changes in the body that may affect the pharmacokinetics of drugs.The present study in 7 normal volunteers and 8 adult male patients with irondeficiency anaemia (IDA) was done to investigate the effect of iron deficiency and its treatment with total dose iron (TDI) on the bioavailability of a single dose of phenytoin. Phenytoin bioavailability was investigated before and 3 and 28 days after TDI.The bioavailability parameters Cmax, tmax, AUC and 2 h phenytoin concentrations were not significantly different in anaemic patients as compared to normal volunteers before or after treatment, except for an increase in tmax 28 days after TDI treatment. 相似文献
12.
目的 观察埃索美拉哗联合左氧氟沙星和阿莫西林一线治疗幽门螺杆菌的疗效.方法 163例幽门螺杆菌阳性患者,随机分为3组,分别应用埃索美拉唑20mg每13 2次(A组),埃索美拉唑40 mg每13 2次(B组),埃索美拉唑40 mg每日1次(C组),3组均加用左氧氟沙星500 mg每日1次和阿莫西林1000 mg每日2次,疗程7 d.并且对幽门螺杆菌根除率分别按意愿治疗(ITT)分析和方案(PP)分析进行评估.结果 A、B、C组各治疗方案的根除率:ITT法为82.98%、87.10%、70.37%;PP法为86.67%、88.52%,73.08%.B组明显高于C组(P<0.05).结论 埃索美拉唑联合左氧氟沙星和阿莫西林一线治疗能显著提高幽门螺杆菌根除率. 相似文献
13.
过敏性紫癜与幽门螺杆菌感染的临床相关性初步探讨 总被引:1,自引:0,他引:1
目的研究幽门螺杆菌感染与过敏性紫癜的临床关系并指导治疗。方法对93例过敏性紫癜患者进行幽门螺杆菌检测,对合并HP感染者在常规治疗基础上进行HP根治并观察其临床疗效。结果93例过敏性紫癜中有41例合并HP感染44.09%,同时行HP根治后过敏性紫癜临床症状迅速消退,恢复快、复发率低,随访2个月~2年效果好。结论HP感染可能是HSP发病的重要因素之一,根治HP有利HSP的治疗康复。 相似文献
14.
N. A. Kshirsagar Y. S. Saraf M. R. Takle M. V. Joshi R. S. Satoskar B. C. Mehta V. N. Acharya 《European journal of clinical pharmacology》1987,33(3):323-325
Summary The effect of iron deficiency anaemia and its treatment on the absorption of sulphadimidine has been investigated in adult patients.The absorption judged by total % of the dose excreted in urine and Cmax, tmax, AUC and Kabs in plasma, was not significantly different before and after iron therapy or correction of anaemia.However, sulphadimidine absorption by the anaemic patients was significantly greater than in normals. 相似文献
15.
目的探讨幽门螺杆菌(Hp)根除治疗在慢性胃炎治疗过程中的临床疗效。方法经胃镜、组织病理学检查和幽门螺杆菌检测确诊为幽门螺杆菌相关性胃炎患者99例分为研究组49例和观察组50例,并以同期53例非幽门螺杆菌相关性胃炎患者作为阴性对照组。研究组给予正规的根除幽门螺杆菌三联治疗,其他各组的基本治疗相同。分析每个组治疗前和治疗后4周、1年~1年6个月随访结束时的症状体征、胃镜检查和组织病理学检查结果。结果治疗结束后4周研究组的炎症严重程度和活动度都比观察组的轻(P<0.05)。研究组的炎症严重程度比治疗前明显好转(P<0.05),观察组则无显著性差异(P>0.05)。研究组的复发率比观察组和阴性对照组的都低(P<0.05)。结论对幽门螺杆菌相关性胃炎患者进行正规的根除幽门螺杆菌治疗可以提高慢性胃炎的临床治疗效果,具有非常重要的临床意义。 相似文献
16.
目的探讨疣状胃炎与幽门螺杆菌(Hp)感染及病理改变的关系。方法观察78例疣状胃炎Hp感染情况、内镜表现及病理改变,同时与随机选择同期检查的慢性胃炎82例进行比较。结果疣状胃炎组Hp感染率显著高于慢性胃炎组,差异有统计学意义(P<0.05);疣状胃炎组Hp感染率随炎症活动程度加重而增高;疣状胃炎组中重度肠上皮化生及不典型增生者均明显高于慢性胃炎组,差异均有统计学意义(P<0.01)。结论Hp感染与疣状胃炎发生发展密切相关;疣状胃炎伴有明显的病理异常,有恶变倾向,应重视诊治和随访。 相似文献
17.
目的:寻找慢性支气管炎患者感染幽门螺杆菌(helicobacter pyloric,Hp)的证据,探讨Hp感染与慢性支气管炎的相关性。方法:分为慢性支气管炎组48例和对照组51例,应用检测血清抗HpIgG及14C-尿素呼气试验方法检测Hp感染情况,并分别测定各组血清C反应蛋白、白细胞总数。结果:慢性支气管炎组患者血清抗HpIgG阳性率为83.3%,明显高于对照组的54.9%,P〈0.05;慢性支气管炎患者Hp现症感染率为81.3%(39/48),明显高于对照组的49.0%(25/51),P〈0.05;慢性支气管炎组Hp现症感染患者血清C反应蛋白、白细胞总数较非Hp感染患者明显升高(P〈0.05)。结论:Hp感染与慢性支气管炎相关,可能是慢性支气管炎发病的潜在致病因素。 相似文献
18.
19.
目的观察嗜酸乳杆菌片联合三联疗法治疗幽门螺杆菌(Hp)感染的疗效。方法 Hp感染患者258例随机分为三组,分别采用雷贝拉唑+克拉霉素+阿莫西林(三联组,86例)、三联组方案+复方嗜酸乳杆菌(益生菌组,85例)和三联组方案+铋剂(四联组,87例)治疗,测定各组胃黏膜IL-8表达,比较Hp根除率和不良反应发生情况。结果益生菌组Hp根除率为80.0%,高于三联组的60.5%(P<0.05)。益生菌组胃黏膜IL-8含量为(60.7±25.1)pg/ml,低于三联组的(73.1±27.7)pg/ml(P<0.05)。益生菌组腹泻、食欲减退、便秘等不良反应发生率低。结论嗜酸乳杆菌联合三联疗法能显著提高Hp根除率,减轻炎症反应,减少抗生素治疗相关不良反应。 相似文献
20.
《Expert opinion on investigational drugs》2013,22(9):995-1016
Successful Helicobacter pylori eradication therapy remains a challenge in medical practice. Currently, a proton pump inhibitor-based triple therapy containing clarithromycin, amoxicillin or nitroimidazole for 7 days is the recommended first-line treatment approach with an expected eradication success rate of ~ 80%. As a second-line treatment option in the case of failure, a ranitidine bismuth citrate-based quadruple therapy is currently recommended curing another 80% of patients, leaving a subset of patients with persistent H. pylori infection. For these patients, promising rescue options have been evaluated including regimens that contain rifabutin, quinolones, furazolidone or high-dose amoxicillin. The role of susceptibility testing is still under discussion. It is not generally recommended prior to first-line treatment but guidelines propose a role for culture and antibiotic sensitivity testing after failure of the second attempt. Meanwhile, data on the geographic distribution of resistance pattern are available and may guide therapeutic decisions with regard to the combination of antibiotics chosen for the individual patients aiming at 100% cure rate in each individual patient. 相似文献